| 肖鹏.替诺福韦、恩替卡韦治疗乙肝肝硬化的效果及对肝功能的影响比较[J].中国医药科学,2023,(20):58-60 基金项目: |
| 替诺福韦、恩替卡韦治疗乙肝肝硬化的效果及对肝功能的影响比较 |
| Comparison of the efficacy of tenofovir and entecavir in the treatment of hepatitis B cirrhosis and the effect on liver function |
| |
| DOI： |
| 中文关键词: 乙肝肝硬化；替诺福韦；恩替卡韦；肝功能 |
| 英文关键词:Hepatitis B cirrhosis; Tenofovir; Entecavir; Liver function |
| 作者 | 单位 | | 肖鹏 | 江苏省邳州市人民医院传染科，江苏邳州 221300 |
|
| 摘要点击次数: 159 |
| 全文下载次数: 264 |
| 中文摘要: |
| [摘要] 目的 探讨替诺福韦和恩替卡韦在乙肝肝硬化患者中的治疗效果以及对肝功能的影响。 方法 抽取92例2020年1月至2022年12月邳州市人民医院传染科收治的乙肝肝硬化患者，采用随机数表法将其分为对照组和试验组，每组各46例。对照组以恩替卡韦治疗，试验组患者采取替诺福韦治疗。比较两组患者治疗结果以及治疗前后肝功能和肝纤维化指标变化。 结果 试验组患者治疗有效率显著高于对照组，差异有统计意义（P < 0.05）；治疗前，两组患者天冬氨酸氨基转移酶（AST）、丙氨酸氨基转移酶（ALT）比较，差异无统计学意义（P > 0.05），治疗后，试验组AST、ALT低于对照组，差异有统计学意义（P < 0.05）；治疗前，两组患者层粘连蛋白（LN）、透明质酸（HA）、Ⅲ型前胶原肽（PⅢP）比较，差异无统计学意义（P > 0.05），治疗后，试验组LN、HA、PⅢP均低于对照组，差异有统计学意义（P < 0.05）。 结论 替诺福韦的治疗较恩替卡韦的治疗效果更佳，替诺福韦治疗后乙肝肝硬化患者肝功能改善更为明显，对患者病情转归有重要意义，值得推广。 |
| 英文摘要: |
| [Abstract] Objective To investigate the efficacy of tenofovir and entecavir in the treatment of patients with hepatitis B cirrhosis and their effect on liver function. Methods A sample of 92 patients with hepatitis B cirrhosis from the Department of Infectious Diseases of Pizhou People’s Hospital admitted from January 2020 to December 2022 was taken. The above patients were divided into the control and experimental groups using the random number table method, with 46 patients in each group. Patients in the control group were treated with entecavir and those in the experimental group were administered tenofovir. The treatment outcomes as well as the changes in liver function and liver fibrosis indicators before and after treatment were compared between the two groups. Results The effective rate of treatment in the experimental group was significantly higher than that in the control group, and the difference was statistically significant (P < 0.05). Before treatment, there was no statistically significant difference in the levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) between the two groups of patients (P > 0.05). After treatment, the AST and ALT levels in the experimental group were lower than those in the control group, with statistically significant difference (P < 0.05). Before treatment, there was no statistically significant difference in the levels of laminin (LN), hyaluronic acid (HA), and typeⅢ procollagen peptide (PⅢP) between the two groups of patients (P > 0.05). After treatment, the LN, HA, and PⅢP levels in the experimental group were lower than those in the control group, with statistically significant difference (P < 0.05). Conclusion Tenofovir treatment improves liver function more significantly in patients with hepatitis B cirrhosis, which is important for the patients' outcome and worth promoting as a treatment option. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
.jpg)